Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - Annexon, Inc. is a biopharmaceutical company focused on developing novel therapies for neuroinflammatory diseases affecting the body, brain, and eye [2] - The company employs a unique scientific approach targeting upstream C1q to inhibit the classical complement inflammatory cascade [2] - Annexon is advancing a late-stage clinical platform with proof-of-concept data in conditions such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy [2] Recent Developments - On July 11, 2024, Annexon granted an equity award to a new non-executive employee under the 2022 Employment Inducement Award Plan [1] - The awarded option allows the purchase of 6,200 shares of Annexon common stock at an exercise price of $6.17, which reflects the closing price on July 15, 2024 [1] - The option has a ten-year term and vests over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter [1]